Abstract:Objective With the introduction of multimodality therapy for cervical cancer, many women will be long-term survivors in need of comprehensive surveillance care. Our goals were to evaluate patterns of obesity and smoking in a cohort of cervical cancer survivors and to assess the potential influence of these comorbidities on subsequent follow-up. Methods We reviewed the records of patients treated for invasive cervical cancer at our institution from 2000 to 2003 who had no evidence of disease for 3 or more years. Demographic and clinical data were collected, including smoking history and anthropometric measurements. Body mass index (BMI) was categorized according to World Health Organization criteria. Logistic regression and Wilcoxon rank sum analyses were performed. Results Two hundred ninety-eight women had complete follow-up data at 3 years. The median age at diagnosis was 43.5 years (range, 17.6–87.1 years). At diagnosis, 31.9% had a normal BMI, 28.2% were overweight, and 34.6% were obese compared with 31.7%, 21.1%, and 30.2% at 3 years, respectively. Of the 51 women whose BMI categorization changed, 33 (64.7%) had weight gain, and 18 (35.3%) had weight loss. By paired analyses, increase in BMI was significant over the 3-year interval (P < 0.001). Seventy patients actively smoked at diagnosis. Compared with nonsmokers, current smokers had a greater odds of referral to the pain service (odds ratio [OR], 6.56; confidence interval [CI], 6.26–16.43; P < 0.001), physical therapy (OR, 4.74; CI, 1.29–17.36; P = 0.02), and gastroenterology (OR, 2.25; CI, 1.14–4.24; P = 0.02). Conclusions Obesity and smoking are significant comorbidities that may complicate care in cervical cancer survivors. Interventions aimed at modifying these risk factors should be routinely undertaken in this population.

Targeted drug delivery system inspired by macropinocytosis

Coating nanoparticles with cell membranes for targeted drug delivery

Revealing macropinocytosis using nanoparticles

Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic

Transporting Carriers for Intracellular Targeting Delivery Via Non-Endocytic Uptake Pathways

Macropinocytosis: an endocytic pathway for internalising large gulps

The Dual Role of Macropinocytosis in Cancers: Promoting Growth and Inducing Methuosis to Participate in Anticancer Therapies as Targets

The Role and Therapeutic Potential of Macropinocytosis in Cancer

“Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems

Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer

Lifestyle Modification in Cervical Cancer Survivors: An Ongoing Need

Macropinocytosis in Different Cell Types: Similarities and Differences

An Overview on Macrophage Targeting: A Promising Approach

Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy.

Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting

Reliability and equivalence in the Eight-Parallel Form Anxiety Battery.

Current Development of Nano-Drug Delivery to Target Macrophages

Multimicrochannel Microneedle Microporation Platform for Enhanced Intracellular Drug Delivery

Recent Development of Drug Delivery Systems through Microfluidics: From Synthesis to Evaluation

Cellular Regulation of Macropinocytosis